Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis

Kidney International

Volumn 56, Issue 3, 1999, Pages 1078-1083

  Boaz, Mona ^a,b,c,d   Matas, Zipora ^a,b,c,d   Biro, Alexander ^a,b,c,d   Katzir, Ze'ev ^a,b,c,d   Green, Manfred ^a,b,c,d   Fainaru, Menahem ^a,b,c,d   Smetana, Shmuel ^a,b,c,d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b Israel Center for Disease Control   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atherosclerosis; CVD; Dialysis; Lipid peroxidation; Maintenance hemodialysis; Oxidative stress

Indexed keywords

FIBRINOGEN; LIPOPROTEIN; MALONALDEHYDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SPECTROPHOTOMETRY;

EID: 0032853944     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00613.x     Document Type: Article

References (43)

1. 1. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1941
2. 2. Haberland ME, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipemic rabbits. Science 241:215-218, 1988
3. 3. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989
4. 4. Salonen JT, Yla-Herttuala S, Yammamoto R, Butler S, Korpela H, Salonen R, Nyyssnen K, Palinski W, Witztum JL: Auto-antibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887, 1992
5. 5. Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183-1186, 1992
6. 6. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 78:6499-6503, 1981
7. 7. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G: Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 53:314S-321S, 1991
8. 8. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of biologically modified low-density lipoprotein. Arteriosclerosis 3:149-159, 1983
9. 9. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoprotein: A potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA 84:2995-2998, 1987
10. 10. Quinn MT, Parthasarathy S, Steinberg D: Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA 82:5949-5953, 1985
11. 11. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente JA, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88:2039-2046, 1991
12. 12. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M: Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 87:904-908, 1990
13. 13. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte-endothelial interactions. J Clin Invest 85:1260-1266, 1990
14. 14. Cathcart MK, Morel DW, Chisholm GM: Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 38:341-350, 1987
15. 15. Morel DW, Hessler JR, Chisolm GM: Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 24:1070-1076, 1983
16. 16. Kugiyama K, Kerns SA, Morrisett JD, Roberts T, Henry PD: Impairment of endothelium-dependent relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160-162, 1990
17. 17. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA: Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 138:601-607, 1991
18. 18. Romero FJ, Bosch-Morell F, Romero MJ, Jareno EJ, Romero B, Marin NM, Roma J: Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect 106(Suppl 5):1229-1234, 1998
19. 19. Diaz J, Serrano E, Acosta F, Carbonell LF: Reference intervals for four biochemistry analytes in plasma for evaluating oxidative stress and lipid peroxidation in human plasma. Clin Chem 44:2215-2217, 1998
20. 20. Pucheu S, Coudray C, Vanzetto G, Favier A, Machecourt J, De Leiris J: Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: Utility of assaying plasma malondialdehyde. Free Radic Biol Med 19:873-881, 1995
21. 21. Nally JV Jr: Cardiac disease in chronic uremia: Investigation. Adv Renal Replace Ther 4:225-233, 1997
22. 22. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
23. 23. Ritz E, Koch M: Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 21(Suppl 2):113-118, 1993
24. 24. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 21:77-80, 1993
25. 25. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS: Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 41:1135-1138, 1995
26. 26. Zima T, Haragsim L, Stipek S, Bartova V, Nemecek K: Lipid peroxidation on dialysis membranes. Biochem Mol Biol Int 29:531-537, 1993
27. 27. Toborek M, Wasik T, Drodz M, Klin M, Magner-Wrobel K, Kopieczna-Grzebieniak E: Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41:1229-1232, 1992
28. 28. Schmidtmann S, Muller M, Von Baehr R, Precht K: Changes of antioxidative homeostasis in patients on chronic hemodialysis. Nephrol Dial Transplant 6(Suppl 3):71-74, 1991
29. 29. Lippa S, Colacicco L, Calla C, Sagliaschi G, Angelitti AG: Coenzyme Q10 levels, plasma lipids and peroxidation extent in renal failure and hemodialytic patients. Mol Aspect Med 15(Suppl):S213-S:219, 1994
30. 30. Peuchant E, Corbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing hemodialysis: Vitamins A, E, and iron status. Free Radic Biol Med 16:339-346, 1994
31. 31. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Gazo A, Nei M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45:876-883, 1994
32. 32. Schettler V, Wieland E, Verwiebe R, Schuff-Werner P, Scheler F, Oellerich M: Plasma lipids are not oxidized during hemodialysis. Nephron 67:42-47, 1994
33. 33. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
34. 34. Bird RP, Draper HH: Comparative studies on different methods of malondialdehyde determination. Methods Enzymol 105:299-305, 1984
35. 35. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499-502, 1972
36. 36. Daurgirdas JT: Second generation logarithmic estimates of singlepool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
37. 37. Cuthbert C, Wang Z, Zhang X, Tam SP: Regulation of human apolipoprotein A-I gene expression by gramoxone. J Biol Chem 272:14954-14960, 1997
38. 38. Bakkaloglu A, Kirel B, Ozen S, Saathi U, Topaloglu Besbas N: Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol 15:341-345, 1996
39. 39. Memon RA, Hussain R, Raynes JG, Lateff A, Chiang TJ: Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins. Int J Lepr Other Mycobact Dis 64:115-122, 1996
40. 40. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assman G: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374-379, 1995
41. 41. Docci D, Bilancioni R, Buscaroli A, Baldrati L, Caponcini C, Mengozzi S, Turci F, Feletti C: Elevated serum levels of C-reactive protein in hemodialysis patients. Nephrologie 56:364-367, 1990
42. 42. Fuhrman B, Judith O, Keidar S, Ben-Yaish L, Kaplan M, Aviram M: Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic Biol Med 23:34-46, 1997
43. 43. Kaysen GA, Stevenson FT, Kepner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:658-668, 1997